Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, Odefsey contains tenofovir alafenamide and emtricitabine and should not be administered with tenofovir-DF or additional emtricitabine (both components of Truvada).
Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. Odefsey should not be co-administered with medicinal products containing tenofovir disproxil.
Odefsey Summary of Product Characteristics, Gilead Sciences Ltd, January 2019.
Because Odefsey is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
Odefsey US Prescribing Information, Gilead Sciences Inc, October 2018.
Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing emtricitabine or tenofovir alafenamide.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking